Connection

THOMAS KOSTEN to Dopamine Plasma Membrane Transport Proteins

This is a "connection" page, showing publications THOMAS KOSTEN has written about Dopamine Plasma Membrane Transport Proteins.
  1. Pharmacogenetic role of dopamine transporter (SLC6A3) variation on response to disulfiram treatment for cocaine addiction. Am J Addict. 2019 07; 28(4):311-317.
    View in: PubMed
    Score: 0.155
  2. Genetic variation of the dopamine transporter (DAT1) influences the acute subjective responses to cocaine in volunteers with cocaine use disorders. Pharmacogenet Genomics. 2015 Jun; 25(6):296-304.
    View in: PubMed
    Score: 0.118
  3. Addiction as a brain disease. Am J Psychiatry. 1998 Jun; 155(6):711-3.
    View in: PubMed
    Score: 0.036
  4. Plasma homovanillic acid and the dopamine transporter during cocaine withdrawal. Biol Psychiatry. 1998 Feb 15; 43(4):278-81.
    View in: PubMed
    Score: 0.036
  5. Prediction of dopamine transporter binding availability by genotype: a preliminary report. Am J Psychiatry. 2000 Oct; 157(10):1700-3.
    View in: PubMed
    Score: 0.011
  6. Elevated central serotonin transporter binding availability in acutely abstinent cocaine-dependent patients. Am J Psychiatry. 2000 Jul; 157(7):1134-40.
    View in: PubMed
    Score: 0.010
  7. Elevated striatal dopamine transporters during acute cocaine abstinence as measured by [123I] beta-CIT SPECT. Am J Psychiatry. 1998 Jun; 155(6):832-4.
    View in: PubMed
    Score: 0.009
  8. [123I]beta-CIT SPECT imaging of dopamine transporter availability after mazindol administration in human cocaine addicts. Psychopharmacology (Berl). 1998 Jun; 137(4):321-5.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.